EROXON Trademark

Trademark Overview

On Thursday, September 21, 2023, a trademark application was filed for EROXON with the United States Patent and Trademark Office. The USPTO has given the EROXON trademark a serial number of 98191073. The federal status of this trademark filing is SU - REGISTRATION REVIEW COMPLETE as of Wednesday, October 1, 2025. This trademark is owned by Futura Medical Developments Limited. The EROXON trademark is filed in the Medical Instrument Products category with the following description:

Medical devices for topical use in the treatment of sexual dysfunction
eroxon

General Information

Serial Number98191073
Word MarkEROXON
Filing DateThursday, September 21, 2023
Status819 - SU - REGISTRATION REVIEW COMPLETE
Status DateWednesday, October 1, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, October 8, 2024

Trademark Statements

Goods and ServicesMedical devices for topical use in the treatment of sexual dysfunction

Classification Information

International Class010 - Surgical, medical, dental, and veterinary apparatus and instruments, artificial limbs, eyes, and teeth; orthopedic articles; suture materials.
US Class Codes026, 039, 044
Class Status Code6 - Active
Class Status DateSunday, October 8, 2023
Primary Code010
First Use Anywhere DateMonday, September 30, 2024
First Use In Commerce DateMonday, September 30, 2024

Trademark Owner History

Party NameFutura Medical Developments Limited
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressGuildford, Surrey GU27YG
GB
Party NameFutura Medical Developments Limited
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressGuildford, Surrey GU27YG
GB

Trademark Events

Event DateEvent Description
Monday, September 25, 2023NEW APPLICATION ENTERED
Sunday, October 8, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, May 15, 2024NON-FINAL ACTION WRITTEN
Wednesday, May 15, 2024ASSIGNED TO EXAMINER
Thursday, August 22, 2024TEAS CHANGE OF OWNER ADDRESS RECEIVED
Thursday, August 22, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, May 15, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, May 15, 2024NON-FINAL ACTION E-MAILED
Thursday, August 15, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, August 22, 2024APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Thursday, August 22, 2024TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, August 22, 2024TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Thursday, August 22, 2024ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, August 22, 2024TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED
Thursday, August 29, 2024FINAL REFUSAL E-MAILED
Friday, August 30, 2024EXAMINERS AMENDMENT E-MAILED
Thursday, August 29, 2024NOTIFICATION OF FINAL REFUSAL EMAILED
Thursday, August 29, 2024FINAL REFUSAL WRITTEN
Friday, August 30, 2024EXAMINERS AMENDMENT -WRITTEN
Friday, August 30, 2024EXAMINER'S AMENDMENT ENTERED
Friday, August 30, 2024NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Friday, August 30, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, September 18, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, October 8, 2024PUBLISHED FOR OPPOSITION
Tuesday, November 19, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, April 29, 2025USE AMENDMENT FILED
Tuesday, April 29, 2025TEAS STATEMENT OF USE RECEIVED
Thursday, May 15, 2025SOU EXTENSION 1 FILED
Wednesday, October 1, 2025SOU EXTENSION 1 GRANTED
Wednesday, October 1, 2025STATEMENT OF USE PROCESSING COMPLETE
Wednesday, October 1, 2025CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, October 1, 2025ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Wednesday, October 1, 2025NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Thursday, October 2, 2025NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, May 16, 2025SOU TEAS EXTENSION RECEIVED
Tuesday, October 8, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

Related Keywords

eroxon sexual dysfunction treatment topical devices medical